A study looking at the HPV test for cervical cancer screening (ARTISTIC)

Cancer type:

Cervical cancer





This study looked at the human papilloma virus (HPV) test and standard cervical smear tests to screen for cervical cancer.

All women in the UK between the ages of 25 and 64 are invited to have a cervical smear test every 3 to 5 years. Doctors know that nearly all women with cervical cancer have HPV. But a large number of women with HPV never go on to develop cervical cancer. In most cases, the infection will clear up by itself. But if it doesn’t, the risk of cervical cells becoming abnormal increases.

HPV testing may identify abnormal cells not detected by the smear test, or show that a smear test is needed sooner than every 3 to 5 years.

The women who took part in this study had a cervical smear and HPV test. The aim was to see if using the HPV test as well as standard smear tests can improve current cervical cancer screening.

Summary of results

This study recruited 24,510 women aged between 20 and 64 who attended routine cervical screening in the Manchester area.

In 2006, the researchers did an early analysis of the results. They looked at the women’s cervical smear and HPV test results. They found links between HPV infection rates, the women’s age and the number of abnormal cervical cells found. The results showed

  • The rate of HPV infection was highest in women under 30 years old, less common in women over 30 and lowest in women over 50
  • At all ages, women with HPV were more likely to have moderate cell changes to their cervix than women without HPV
  • About 9 out of 10 women (90%) with severe cell changes (‘severe dyskaryosis’) had HPV

The trial team published more results in 2009. By then, the women taking part had had a 2nd round of screening. The researchers found there was a drop in the number of women who had pre cancerous cells on the cervix at the 2nd screening. When they analysed the results, they found that over two rounds having both an HPV test and cervical smear did not pick up more pre cancerous cells (CIN2 or CIN3 Open a glossary item) than a smear test alone.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Henry Kitchener

Supported by

NIHR Health Technology Assessment (HTA) programme
University of Manchester

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 271

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page